Undifferentiated Sarcoma: Symptoms, Treatment, and Prognosis

Undifferentiated sarcoma is a rare, aggressive soft-tissue cancer that, by definition, shows no recognizable line of cellular differentiation when examined under a microscope. It is essentially a diagnosis of exclusion: pathologists arrive at it only after ruling out every other identifiable sarcoma subtype. The most common form, undifferentiated pleomorphic sarcoma (UPS), accounts for a significant share of adult soft-tissue sarcomas and carries five-year overall survival rates that vary widely by stage, ranging roughly from the mid-50s to the mid-70s percent in published series. Because the tumor lacks a single defining molecular driver, treatment relies on a combination of surgery, radiation, and chemotherapy, though immunotherapy has emerged as a genuinely promising option for a subset of patients.

What “Undifferentiated” Means in Practice

Most cancers can be traced to a specific cell type. A liposarcoma, for instance, resembles fat cells; a leiomyosarcoma resembles smooth muscle. Undifferentiated sarcomas resist that classification. The World Health Organization defines them as tumors showing no identifiable line of differentiation when analyzed with all currently available technologies, making them a markedly heterogeneous group.¹ This heterogeneity is not just a classification quirk. It shapes everything about how the disease behaves, how it responds to treatment, and why researchers have struggled to find targeted therapies for it.

The term has an awkward history. For decades these tumors were called malignant fibrous histiocytoma (MFH), a label coined in 1963 under the assumption that they arose from histiocytes. After years of debate, pathologists concluded that the cellular origin was essentially unresolvable, and MFH was reclassified as synonymous with high-grade undifferentiated pleomorphic sarcoma.² You may still encounter the older MFH terminology in medical records, older literature, or pathology reports, but it refers to the same disease.

Symptoms and Where It Appears

UPS most often arises in the extremities, particularly the thigh, but it can develop almost anywhere in the body, including the trunk, the retroperitoneum (the space behind the abdominal organs), and rarely in organs like the lung or heart. It typically presents as a painless, enlarging mass. Many patients notice a lump growing over weeks to months before seeking medical attention, and pain may develop only when the tumor presses on nerves or other structures. Because the mass can grow deep within muscle, it sometimes reaches a substantial size before it becomes visible or symptomatic.

There are no blood tests or screening tools that reliably catch undifferentiated sarcoma early. The warning signs are nonspecific:

Growing mass: A new lump that increases in size over weeks, especially if deep-seated and larger than about 5 cm.
Pain or stiffness: Occurs when the tumor encroaches on nerves, joints, or adjacent structures.
Swelling or firmness: Sometimes felt before any discrete lump is visible, particularly in the retroperitoneum or trunk.
Systemic symptoms: Rarely, weight loss or fatigue in advanced cases, but these are late features rather than early clues.

The general guideline used by sarcoma specialists is that any soft-tissue mass larger than 5 cm, any mass that is growing, or any mass that is deep to the fascia (the membrane covering muscles) should be investigated further with imaging and biopsy.

How It Is Diagnosed

Imaging usually starts with MRI for extremity and trunk lesions. MRI can reveal internal characteristics of the tumor that help distinguish aggressive tumors from benign lumps. Specific features on MRI that correlate with high-grade UPS include a diffuse, infiltrative growth pattern, substantial internal necrosis (dead tissue within the tumor), and heterogeneous signal on certain imaging sequences.³ These features combined can predict tumor grade with reasonable accuracy, but imaging alone cannot make the diagnosis. A tissue sample is always needed.

Core needle biopsy (CNB) has become the preferred initial approach. A systematic review and meta-analysis found that CNB correctly identifies whether a soft-tissue mass is malignant with about 97% sensitivity and identifies the specific tumor type about 88% of the time, with a significantly lower complication rate than open surgical biopsy.⁴ A sarcoma-center analysis of nearly 400 consecutive patients who underwent ultrasound-guided CNB found that the biopsy result matched the final surgical pathology in about 93% of cases for tumor type and about 93% for tumor grade, with major complications occurring in under 1% of patients.⁵ That said, the biopsy should be planned carefully, ideally by an orthopedic oncologist or sarcoma specialist, because the needle tract may need to be removed during the definitive surgery. In soft-tissue masses with large necrotic areas or unusual locations, needle biopsy can sometimes yield insufficient tissue, and open biopsy may be needed.⁶

Under the microscope, pathologists look at how bizarre and varied the cells appear, how many cells are dividing, and how much necrosis is present. These features feed into the FNCLCC grading system, which assigns a grade from 1 to 3. Both the FNCLCC and the older NCI grading system predict the likelihood of metastasis and death, but multivariate analyses have found that tumor grade carries more prognostic weight than tumor size or depth.⁷

Surgery and the Margin Question

Wide surgical removal is the backbone of treatment for localized UPS. The goal is to excise the tumor with a cuff of healthy tissue around it. But how wide that cuff needs to be has real consequences for function, especially when the tumor sits near joints, nerves, or blood vessels. A study examining margin quality in UPS and the closely related myxofibrosarcoma found that margins of 10 mm or greater dropped the five-year local recurrence rate to about 3%, compared with roughly 22% when margins were positive (tumor touching the inked edge of the specimen).⁸ Margins between 0.1 and 9.9 mm fell somewhere in between, though the quality of the tissue barrier at the margin (for instance, whether intact fascia or bone served as the boundary) also mattered. For some patients, achieving wide margins would mean amputating a limb, and in those situations, surgeons aim for the narrowest safe margin combined with radiation therapy.

Radiation Therapy

Radiation is commonly paired with surgery, and the major question for patients and oncologists is whether it should be given before or after the operation. A landmark randomized trial found that preoperative radiation led to more wound complications, with about 35% of patients experiencing wound problems compared with 17% in the postoperative group.⁹ However, overall survival was slightly better in the preoperative group, and a later follow-up of the same trial showed that patients who received postoperative radiation had more long-term side effects: roughly 48% developed moderate or worse fibrosis (hardening of tissue) compared with about 32% in the preoperative arm, and edema and joint stiffness also trended higher in the postoperative group.¹⁰

The practical takeaway is a trade-off: preoperative radiation uses a lower dose, tends to cause fewer late functional problems, and may offer a slight survival edge, but it raises the risk of wound healing trouble right after surgery. Postoperative radiation avoids wound issues but delivers a higher dose to a larger field and produces more long-term stiffness and swelling. Most sarcoma centers now lean toward preoperative radiation for extremity tumors, especially when the wound can be managed with plastic surgery techniques, though the decision still depends on tumor size and location.

Chemotherapy

The role of chemotherapy in UPS is less clear-cut than surgery or radiation, and this is one of the areas where the evidence gets genuinely frustrating. Doxorubicin-based regimens, often combined with ifosfamide, are the standard first-line options for advanced or high-risk disease. A 14-year institutional experience found that ifosfamide-doxorubicin independently improved distant metastasis-free survival, disease-specific survival, and overall survival on multivariate analysis, though some of that benefit weakened after matching patients for other prognostic factors.¹¹ Tumor size above 10 cm and trunk location were also independent risk factors for worse outcomes in that analysis, suggesting that chemotherapy helps the most in patients who already face long odds.

Newer combination regimens are being tested. A phase 2 trial combining the immune checkpoint inhibitor sintilimab with doxorubicin and ifosfamide as front-line treatment in advanced sarcoma patients reported an overall response rate of about 88% in the UPS subgroup (seven of eight patients), with a median progression-free survival of 9 months and a median overall survival of about 20 months across the full trial cohort.¹² Those numbers look promising, but this was a small, single-arm study and will need confirmation in larger trials.

Immunotherapy

Among the many subtypes of soft-tissue sarcoma, UPS has shown one of the highest response rates to immune checkpoint inhibitors. The SARC028 trial, which tested pembrolizumab across multiple sarcoma subtypes, found that four of ten evaluable UPS patients responded, including one complete response lasting more than 13 months.¹³ That 40% response rate stood out sharply against most other sarcoma subtypes, where single-agent checkpoint inhibitors typically achieve response rates in the single digits or low teens.

There are biological reasons why UPS responds better. Studies of the tumor microenvironment have found that UPS tumors are infiltrated with CD8-positive T cells that express high levels of PD-1, the receptor that checkpoint inhibitors block.¹⁴ The tumor essentially attracts immune cells that are capable of attacking it, then shuts them down. Blocking PD-1 with drugs like pembrolizumab can reactivate those T cells. More recent spatial transcriptomics work has added nuance, showing that the immune landscape within a single UPS tumor can vary dramatically from region to region, with some zones dominated by macrophages that may promote immune suppression and others containing active T cells.¹⁵ Understanding which patients will respond and which will not remains an active area of research.

Individual case reports have documented durable responses. One patient with metastatic UPS received continuous pembrolizumab for over six and a half years (109 cycles), with sustained benefit and no significant side effects, occasionally supplemented by radiation to address emerging lesions.¹⁶ A single case report does not define a treatment strategy, but it illustrates the ceiling of what immunotherapy can achieve in this disease.

Targeted Therapy

Because UPS lacks a consistent molecular driver, the landscape for targeted therapy is sparse compared with cancers that have well-defined mutations. Pazopanib, a multi-target drug that blocks several growth-signaling pathways, is approved for advanced soft-tissue sarcomas after chemotherapy failure. A phase 2 study testing pazopanib as front-line treatment in patients unfit for chemotherapy reported a median progression-free survival of about 3.7 months and a clinical benefit rate of roughly 39%.¹⁷ A separate study focusing on rare sarcoma subtypes, including UPS, found a median progression-free survival of about 10 months and an objective response rate of 27%.¹⁸

The occasional dramatic responder hints at what molecular profiling might one day achieve. A case report described a UPS patient whose tumor harbored amplification of three specific growth-signaling genes and who achieved a sustained three-year response to pazopanib with no new lesions.¹⁹ The broader challenge is that UPS tumors exhibit a wide range of genetic abnormalities, including activating and inactivating mutations, gene amplifications, and chromosomal rearrangements, with no single dominant alteration that could serve as a universal target.²⁰ Mutations in TP53 and deletions of CDKN2A are among the most frequently observed changes, but they are tumor suppressors rather than druggable oncogenes, which limits their current therapeutic utility.²¹

Prognosis and What Drives It

Published five-year overall survival rates for UPS cluster in the range of roughly 53% to 76%, depending on the patient population and the proportion of early- versus late-stage disease in the series. A long-term institutional follow-up reported a five-year overall survival of 53% and a five-year metastasis-free survival of 70%, with tumor presentation (primary versus recurrent), size, and involvement of critical structures all emerging as independent prognostic factors.²² A 20-year study of 266 patients found a five-year survival rate of 60% and a ten-year rate of 48%, with a median survival time of about ten years.²³ A third series of 166 patients focused on extremity and trunk tumors reported a more favorable five-year rate of about 76%.²⁴ The spread reflects differences in how advanced the disease was at diagnosis and where the tumors were located.

The lungs are the most common destination for metastatic disease. In a large tertiary center study, about 77% of patients who developed metastases had them in the lungs.²⁵ Across soft-tissue sarcomas broadly, about 20% of patients with extremity tumors develop isolated lung metastases at some point during their disease course.²⁶ This is why surveillance CT scans of the chest are a standard part of follow-up after treatment. Local recurrence is also a persistent concern, particularly in UPS arising in the trunk or retroperitoneum, and surveillance MRI of the primary site is recommended for years after resection. Post-treatment MRI should be interpreted carefully: enhancing tissue along fascial planes near the operative bed suggests recurrence rather than scar tissue, and any enlargement over time warrants biopsy.²⁷

Radiation-Induced Undifferentiated Sarcoma

A small but clinically important subset of UPS cases arise in areas previously treated with radiation for another cancer. These radiation-associated tumors made up about 5% of the UPS population in one large analysis, with a median gap of about nine years between the original radiation and the sarcoma diagnosis. Outcomes for radiation-associated UPS are significantly worse: five-year disease-specific survival was about 52% compared with roughly 73% for matched sporadic cases, and local recurrence rates were more than double (about 55% versus 24%).²⁸ Radiation-associated status and incomplete resection were both independent predictors of recurrence. This does not mean patients should refuse radiation for their primary cancer; the absolute risk of developing a sarcoma after radiation therapy is very low. But any new mass arising in a previously irradiated field, even years later, deserves prompt evaluation.

Undifferentiated Sarcoma in Children and Young Adults

Undifferentiated sarcoma in children looks different at the molecular level. A Children’s Oncology Group study found that pediatric undifferentiated sarcomas frequently harbor oncogenic gene fusions, with known fusions identified in eight of ten cases tested by next-generation sequencing. Certain chromosomal changes, particularly the combination of 1p loss and 1q gain, were associated with especially poor outcomes, with a five-year event-free survival of just 20%.²⁹ A comprehensive comparison across age groups found that pediatric and young-adult UPS patients had better disease-specific and progression-free survival than adult patients. Pediatric tumors also showed a lower degree of overall genomic disruption, and certain alterations common in adult UPS, like RB1 loss, were absent in the youngest patients.³⁰ The clinical implication is that pediatric undifferentiated sarcomas, while sharing the same broad label, may actually be biologically distinct entities from their adult counterparts, and treatment strategies developed for adults may not always apply.

Life After Treatment

Surviving UPS often means living with lasting physical effects from the surgery and radiation. A study of soft-tissue sarcoma survivors treated with limb-sparing surgery found that patients scored relatively well on standardized functional assessments, with mean scores around 86 out of 100 on a musculoskeletal function scale and about 75 out of 100 on a quality-of-life physical functioning scale.³¹ Those averages are encouraging but mask wide individual variation. A separate analysis found that among the different ways to measure function, restrictions on social participation (the ability to work, travel, and carry out daily roles) had the single largest impact on overall quality of life, explaining more of the variation than physical impairment or activity limitations alone.³² For patients and rehabilitation teams, that finding argues for prioritizing the activities and roles that matter most to the individual, rather than focusing narrowly on range of motion or strength in isolation.